Results 11 to 20 of about 180,865 (263)

Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report

Respiratory Medicine Case Reports, 2020
We herein report a non-smoking 81-year-old man with advanced synchronous multiple primary lung cancers (SMPLC), containing squamous cell carcinoma with strong programmed death-ligand 1 expression in the middle lobe and adenocarcinoma with epidermal ...
Hirokazu Tokuyasu, Mika Horie, Soichiro Ishikawa, Hiromitsu Sakai, Hiroshi Miura, Akira Yamasaki   +5 more
doaj   +1 more source

The journey of dostarlimab: a successful weapon for cancer treatment

Exploration of Medicine, 2022
In a number of malignancies, new immuno-oncology therapies that focus on the programmed cell death 1 (PD-1) have improvised the patient condition along with a positive aftereffect. Monoclonal antibodies (mAbs) directed against PD-1 and its ligand (PD-L1),
Rouchan Ali, Sharma Arvind Virendra, Pooja A. Chawla   +2 more
doaj   +1 more source

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy

Frontiers in Immunology, 2022
Antibodies targeting programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) have been considered breakthrough therapies for a variety of solid and hematological malignancies.
Rilan Bai, Jiuwei Cui
doaj   +1 more source

A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma

Acta Dermato-Venereologica, 2022
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma.
Camille Luherne, Sarah Menguy, Thomas Ferte, Marie Beylot-Barry, Julien Seneschal, Brigitte Milpied, Jean-Philippe Vial, Audrey Gros, Samuel Amintas, Béatrice Vergier, Anne Pham-Ledard   +10 more
doaj   +1 more source

Changes and correlations of T-cell coinhibitory molecule programmed death-1 and interferon-γ in pediatric immune thrombocytopenia [PDF]

Clinical and Experimental Pediatrics, 2023
Background Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by abnormalities of T cells subsets. Programmed death-1 (PD-1) is a co-signaling inhibitory molecule in T cells that is involved in many autoimmune diseases. Purpose
Fady Mohamed El-Gendy, Amira M.F. Shehata, Esam Awad Abd El-Kawy, Mahmoud Ahmed El-Hawy   +3 more
doaj   +1 more source

Programmed Cell Death in Sepsis Associated Acute Kidney Injury

Frontiers in Medicine, 2022
Sepsis-associated acute kidney injury (SA-AKI) is common in patients with severe sepsis, and has a high incidence rate and high mortality rate in ICU patients. Most patients progress to AKI before drug treatment is initiated.
Zhifen Wu, Junhui Deng, Hongwen Zhou, Wei Tan, Lirong Lin, Jurong Yang   +5 more
doaj   +1 more source

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway

BMC Medicine, 2021
Background Chimeric antigen receptor T (CAR-T) cell therapy has limited effects in the treatment of solid tumors. Sulforaphane (SFN) is known to play an important role in inhibiting tumor growth, but its effect on CAR-T cells remains unclear. The goal of
Chunyi Shen, Zhen Zhang, Yonggui Tian, Feng Li, Lingxiao Zhou, Wenyi Jiang, Li Yang, Bin Zhang, Liping Wang, Yi Zhang   +9 more
doaj   +1 more source

The role of PD-1 signaling in health and immune-related diseases

Frontiers in Immunology, 2023
Programmed cell death 1 receptor (PD-1) and its ligands constitute an inhibitory pathway to mediate the mechanism of immune tolerance and provide immune homeostasis.
Ru-Yue Chen, Yun Zhu, Yun-Yan Shen, Qin-Ying Xu, Han-Yun Tang, Ning-Xun Cui, Lu Jiang, Xiao-Mei Dai, Wei-Qing Chen, Qiang Lin, Xiao-Zhong Li   +10 more
doaj   +1 more source

Gut Microbiota Modulates the Efficiency of Programmed Cell Death Protein 1 Cancer Immunotherapies

Iranian Journal of Allergy, Asthma and Immunology, 2022
Program cell death protein 1 (PD1) is considered as an inhibitory molecule that is expressed on the surface of activated T-cells and bound to PD-L1 and PD-L2 ligands.
Azam Samei, Mostafa Khedri
doaj   +1 more source

The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy

Sultan Qaboos University Medical Journal, 2019
Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint ...
Malika Al-Dughaishi, Asem Shalaby, Khawla Al-Ribkhi, Ammar Boudaka, Mohamed-Rachid Boulassel, Jumana Saleh   +5 more
doaj   +1 more source